Table 2.
Baseline characteristics
| Characteristics |
N = 70 N (%) |
|---|---|
| Patient characteristics | |
| Male | 57 (81.4) |
| Age, mean, (SD), years | 65.5 ± 10.1 |
| Body mass index, mean, (SD) | 28.0 ± 3.2 |
| Current smoker | 14 (20.3) |
| Ex-smoker (>6 weeks) | 19 (27.5) |
| Family history for CAD | 8 (12.1) |
| Medical history | |
| Hypertension | 58 (82.9) |
| Diabetes mellitus | 21 (30.0) |
| Dyslipidaemia | 37 (52.9) |
| Angina pectoris month prior to surgery* | 50 (71.4) |
| TIA/Stroke | 6 (8.6) |
| COPD | 6 (8.6) |
| Chronic kidney disease (eGFR MDRD4 < 60 ml/min) | 3 (4.3) |
| Peripheral arterial disease | 3 (4.3) |
| Heart failure (NYHA class III or IV) | 9 (12.9) |
| ACS | 39 (55.7) |
| – MI | 34 (48.6) |
| Prior PCI | 18 (26.1) |
| – PCI + Stent | 11 (15.7) |
| Prior CABG | 0 (0.0) |
| Preoperative medication use | |
| Oral nitrates | 15 (21.4) |
| Beta-blockers | 57 (81.4) |
| ACE inhibitor | 38 (54.3) |
| AT-II-antagonists | 17 (24.3) |
| Diuretics | 18 (25.7) |
| Statins and other lipid-lowering drugs | 67 (95.7) |
| Oral antidiabetics | 16 (22.9) |
| Insulin | 8 (11.4) |
| Surgery | |
| Coronary artery disease | |
| – One vessel | 10 (14.3) |
| – Two vessel | 9 (12.9) |
| – Three vessel | 51 (72.9) |
| Timing | |
| – Elective/planned | 66 (94.3) |
| – Urgent | 2 (2.9) |
| – Emergency | 2 (2.9) |
| EuroScore (SD) | 3.2 ± 2.6 |
Data are presented as number and percentage unless otherwise indicated. Denominators to derive percentages are based on available data for each characteristic. *Any Canadian Cardiovascular Society class angina
ACE angiotensin-converting-enzyme, ACS acute coronary syndrome, AT-II Angiotensine-II, CABG coronary artery bypass grafting, CAD coronary artery disease, COPD chronic obstructive pulmonary disease. eGFR MDRD: estimated glomerular filtration rate according to the modification of diet in renal disease formula, CVA cerebral vascular accident, TIA transient ischaemic attack, LMWH low-molecular-weight heparin, MI myocardial infarction, N number of patients, NYHA New York Heart Association functional classification, (N)OAC (non-)vitamin K antagonist oral anticoagulant, PCI percutaneous coronary intervention, SD standard deviation